Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Stem and Progenitor Cell-Based Therapy of the Central Nervous System : Hopes, Hype, and Wishful Thinking. / Goldman, Steven A.

In: Cell Stem Cell, Vol. 18, No. 2, 04.02.2016, p. 174-188.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Goldman, SA 2016, 'Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking', Cell Stem Cell, vol. 18, no. 2, pp. 174-188. https://doi.org/10.1016/j.stem.2016.01.012

APA

Goldman, S. A. (2016). Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking. Cell Stem Cell, 18(2), 174-188. https://doi.org/10.1016/j.stem.2016.01.012

Vancouver

Goldman SA. Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking. Cell Stem Cell. 2016 Feb 4;18(2):174-188. https://doi.org/10.1016/j.stem.2016.01.012

Author

Goldman, Steven A. / Stem and Progenitor Cell-Based Therapy of the Central Nervous System : Hopes, Hype, and Wishful Thinking. In: Cell Stem Cell. 2016 ; Vol. 18, No. 2. pp. 174-188.

Bibtex

@article{b6bc3f3a98a543b0a9c1d524bd8e251e,
title = "Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking",
abstract = "A variety of neurological disorders are attractive targets for stem and progenitor cell-based therapy. Yet many conditions are not, whether by virtue of an inhospitable disease environment, poorly understood pathophysiology, or poor alignment of donor cell capabilities with patient needs. Moreover, some disorders may be medically feasible targets but are not practicable, in light of already available treatments, poor risk-benefit and cost-benefit profiles, or resource limitations. This Perspective seeks to define those neurological conditions most appropriate for cell replacement therapy by considering its potential efficacy and clinical feasibility in those disorders, as well as potential impediments to its application.",
keywords = "Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review",
author = "Goldman, {Steven A.}",
note = "Copyright {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = feb,
day = "4",
doi = "10.1016/j.stem.2016.01.012",
language = "English",
volume = "18",
pages = "174--188",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "2",

}

RIS

TY - JOUR

T1 - Stem and Progenitor Cell-Based Therapy of the Central Nervous System

T2 - Hopes, Hype, and Wishful Thinking

AU - Goldman, Steven A.

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/2/4

Y1 - 2016/2/4

N2 - A variety of neurological disorders are attractive targets for stem and progenitor cell-based therapy. Yet many conditions are not, whether by virtue of an inhospitable disease environment, poorly understood pathophysiology, or poor alignment of donor cell capabilities with patient needs. Moreover, some disorders may be medically feasible targets but are not practicable, in light of already available treatments, poor risk-benefit and cost-benefit profiles, or resource limitations. This Perspective seeks to define those neurological conditions most appropriate for cell replacement therapy by considering its potential efficacy and clinical feasibility in those disorders, as well as potential impediments to its application.

AB - A variety of neurological disorders are attractive targets for stem and progenitor cell-based therapy. Yet many conditions are not, whether by virtue of an inhospitable disease environment, poorly understood pathophysiology, or poor alignment of donor cell capabilities with patient needs. Moreover, some disorders may be medically feasible targets but are not practicable, in light of already available treatments, poor risk-benefit and cost-benefit profiles, or resource limitations. This Perspective seeks to define those neurological conditions most appropriate for cell replacement therapy by considering its potential efficacy and clinical feasibility in those disorders, as well as potential impediments to its application.

KW - Journal Article

KW - Research Support, N.I.H., Extramural

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.stem.2016.01.012

DO - 10.1016/j.stem.2016.01.012

M3 - Journal article

C2 - 26849304

VL - 18

SP - 174

EP - 188

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 2

ER -

ID: 164972245